Influence of temperature management at 33 °C versus normothermia on survival in patients with vasopressor support after out-of-hospital cardiac arrest: a post hoc analysis of the TTM-2 trial

Joachim Düring, Martin Annborn, Alain Cariou, Michelle S Chew, Josef Dankiewicz, Hans Friberg, Matthias Haenggi, Zana Haxhija, Janus C Jakobsen, Halvor Langeland, Fabio Silvio Taccone, Matthew Thomas, Susann Ullén, Matt P Wise, Niklas Nielsen, Joachim Düring, Martin Annborn, Alain Cariou, Michelle S Chew, Josef Dankiewicz, Hans Friberg, Matthias Haenggi, Zana Haxhija, Janus C Jakobsen, Halvor Langeland, Fabio Silvio Taccone, Matthew Thomas, Susann Ullén, Matt P Wise, Niklas Nielsen

Abstract

Background: Targeted temperature management at 33 °C (TTM33) has been employed in effort to mitigate brain injury in unconscious survivors of out-of-hospital cardiac arrest (OHCA). Current guidelines recommend prevention of fever, not excluding TTM33. The main objective of this study was to investigate if TTM33 is associated with mortality in patients with vasopressor support on admission after OHCA.

Methods: We performed a post hoc analysis of patients included in the TTM-2 trial, an international, multicenter trial, investigating outcomes in unconscious adult OHCA patients randomized to TTM33 versus normothermia. Patients were grouped according to level of circulatory support on admission: (1) no-vasopressor support, mean arterial blood pressure (MAP) ≥ 70 mmHg; (2) moderate-vasopressor support MAP < 70 mmHg or any dose of dopamine/dobutamine or noradrenaline/adrenaline dose ≤ 0.25 µg/kg/min; and (3) high-vasopressor support, noradrenaline/adrenaline dose > 0.25 µg/kg/min. Hazard ratios with TTM33 were calculated for all-cause 180-day mortality in these groups.

Results: The TTM-2 trial enrolled 1900 patients. Data on primary outcome were available for 1850 patients, with 662, 896, and 292 patients in the, no-, moderate-, or high-vasopressor support groups, respectively. Hazard ratio for 180-day mortality was 1.04 [98.3% CI 0.78-1.39] in the no-, 1.22 [98.3% CI 0.97-1.53] in the moderate-, and 0.97 [98.3% CI 0.68-1.38] in the high-vasopressor support groups with regard to TTM33. Results were consistent in an imputed, adjusted sensitivity analysis.

Conclusions: In this exploratory analysis, temperature control at 33 °C after OHCA, compared to normothermia, was not associated with higher incidence of death in patients stratified according to vasopressor support on admission. Trial registration Clinical trials identifier NCT02908308 , registered September 20, 2016.

Keywords: Cardiac arrest; Heart arrest; Hypothermia induced; Mortality; Shock; Sudden.

Conflict of interest statement

JD: No financial or non-financial competing interests. MA: No financial or non-financial competing interests. AC: Received fees for lectures from Bard. MC: No financial or non-financial competing interests. JD: No financial or non-financial competing interests. HF: TEQCool (Lund, Sweden) Academic advisor. MH: No financial or non-financial competing interests. ZH: No financial or non-financial competing interests. JCJ: No financial or non-financial competing interests. HL: No financial or non-financial competing interests. FT: No financial or non-financial competing interests. MT: No financial competing interests, co-applicant on several NIHR cardiac arrest trials but not in the field of temperature management. SU: No financial or non-financial competing interests. MPW: No financial or non-financial competing interests. NN: No financial or non-financial competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Probability of survival. Kaplan–Meier graph censored at 180 days indicating probability of survival in subgroups of vasopressor support on admission, stratified according to temperature intervention. No-vasopressor support, mean arterial blood pressure (MAP) ≥ 70 with no inotropic or vasopressor support; moderate-vasopressor support, MAP  0.25 µg/kg/min. Colored numbers at bottom of plot illustrate number of patients at risk in respective strata at specified timepoint. The vertical tick-marks correspond to censored data. Hazard ratios (HR) are presented with 95% confidence intervals; TTM33, targeted temperature management at 33 °C
Fig. 2
Fig. 2
Cause of death. Kaplan–Meier graph censored at 30 days indicating cumulative risk of non-neurological versus neurological mortality in subgroups of vasopressor support on admission, stratified according to temperature intervention. No-vasopressor support, mean arterial blood pressure (MAP) ≥ 70 with no inotropic or vasopressor support; moderate-vasopressor support, MAP  0.25 µg/kg/min. Colored numbers at bottom of plot illustrate number of patients at risk in respective strata at specified timepoint. The vertical tick-marks correspond to censored data. Hazard ratios (HR) are presented with 95% confidence intervals; TTM33, targeted temperature management at 33 °C
Fig. 3
Fig. 3
Circulatory status day 1–4. Graph illustrating the distribution of highest recorded circulatory support for each day. Patients are categorized according to vasopressor support on admission and stratified according to temperature intervention. No-vasopressor support, mean arterial blood pressure (MAP) ≥ 70 with no inotropic or vasopressor support; moderate-vasopressor support, MAP  0.25 µg/kg/min. D/C, Discharge; ICU, Intensive care unit; Normo; normothermia; and TTM33, targeted temperature management at 33 °C
Fig. 4
Fig. 4
Hemodynamics 0–72 h. Heart rate, mean arterial pressure, and lactate during the 0–72 h after randomization in groups of different levels of circulatory support on admission and stratified by temperature intervention at 33 °C versus normothermia. No-vasopressor support, mean arterial blood pressure (MAP) ≥ 70 with no inotropic or vasopressor support; moderate-vasopressor support, MAP  0.25 µg/kg/min. Boxes represent the interquartile range (IQR), with medians marked as vertical bands. Whiskers symbolize 1.5 × IQR, and dots outside this range represent outliers. TTM33; Targeted temperature management at 33 °C. *p < 0.003; **p < 0.0001; ***p < 0.00001

References

    1. Olai H, Thorneus G, Watson H, Macleod M, Rhodes J, Friberg H, Nielsen N, Cronberg T, Deierborg T. Meta-analysis of targeted temperature management in animal models of cardiac arrest. Intensive Care Med Exp. 2020;8(1):3. doi: 10.1186/s40635-019-0291-9.
    1. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002;346(8):557–563. doi: 10.1056/NEJMoa003289.
    1. Hypothermia after Cardiac Arrest Study G Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002;346(8):549–556. doi: 10.1056/NEJMoa012689.
    1. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, Horn J, Hovdenes J, Kjaergaard J, Kuiper M, et al. Targeted temperature management at 33 degrees C versus 36 °C after cardiac arrest. N Engl J Med. 2013;369(23):2197–2206. doi: 10.1056/NEJMoa1310519.
    1. Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, Rylander C, Wise MP, Oddo M, Cariou A, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest. N Engl J Med. 2021;384(24):2283–2294. doi: 10.1056/NEJMoa2100591.
    1. Sandroni C, Nolan JP, Andersen LW, Bottiger BW, Cariou A, Cronberg T, Friberg H, Genbrugge C, Lilja G, Morley PT, et al. ERC-ESICM guidelines on temperature control after cardiac arrest in adults. Intensive Care Med. 2022;48:261–269. doi: 10.1007/s00134-022-06620-5.
    1. Bro-Jeppesen J, Hassager C, Wanscher M, Ostergaard M, Nielsen N, Erlinge D, Friberg H, Kober L, Kjaergaard J. Targeted temperature management at 33 °C versus 36 °C and impact on systemic vascular resistance and myocardial function after out-of-hospital cardiac arrest: a sub-study of the Target Temperature Management Trial. Circ Cardiovasc Interv. 2014;7(5):663–672. doi: 10.1161/CIRCINTERVENTIONS.114.001556.
    1. Annborn M, Bro-Jeppesen J, Nielsen N, Ullen S, Kjaergaard J, Hassager C, Wanscher M, Hovdenes J, Pellis T, Pelosi P, et al. The association of targeted temperature management at 33 and 36 °C with outcome in patients with moderate shock on admission after out-of-hospital cardiac arrest: a post hoc analysis of the Target Temperature Management trial. Intensive Care Med. 2014;40(9):1210–1219. doi: 10.1007/s00134-014-3375-8.
    1. Soar J, Berg KM, Andersen LW, Böttiger BW, Cacciola S, Callaway CW, Couper K, Cronberg T, D’Arrigo S, Deakin CD, et al. Adult advanced life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation. 2020;156:A80–A119. doi: 10.1016/j.resuscitation.2020.09.012.
    1. Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Belohlavek J, Callaway C, Cariou A, Eastwood G, Erlinge D, Hovdenes J, et al. Targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (TTM2): a randomized clinical trial-rationale and design. Am Heart J. 2019;217:23–31. doi: 10.1016/j.ahj.2019.06.012.
    1. Jakobsen JC, Dankiewicz J, Lange T, Cronberg T, Lilja G, Levin H, Belohlavek J, Callaway C, Cariou A, Erlinge D, et al. Targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest: a statistical analysis plan. Trials. 2020;21(1):831. doi: 10.1186/s13063-020-04654-y.
    1. Callaway CW, Coppler PJ, Faro J, Puyana JS, Solanki P, Dezfulian C, Doshi AA, Elmer J, Frisch A, Guyette FX, et al. Association of initial illness severity and outcomes after cardiac arrest with targeted temperature management at 36 °C or 33 °C. JAMA Netw Open. 2020;3(7):e208215. doi: 10.1001/jamanetworkopen.2020.8215.
    1. Okazaki T, Hifumi T, Kawakita K, Kuroda Y, Japanese Association for Acute Medicine Out-of-Hospital Cardiac Arrest R Targeted temperature management guided by the severity of hyperlactatemia for out-of-hospital cardiac arrest patients: a post hoc analysis of a nationwide, multicenter prospective registry. Ann Intensive Care. 2019;9(1):127. doi: 10.1186/s13613-019-0603-y.
    1. Nishikimi M, Ogura T, Nishida K, Hayashida K, Emoto R, Matsui S, Matsuda N, Iwami T. Outcome related to level of targeted temperature management in postcardiac arrest syndrome of low, moderate, and high severities: a nationwide multicenter prospective registry. Crit Care Med. 2021;49(8):e741–e750.
    1. Lascarrou JB, Merdji H, Le Gouge A, Colin G, Grillet G, Girardie P, Coupez E, Dequin PF, Cariou A, Boulain T, et al. Targeted temperature management for cardiac arrest with nonshockable rhythm. N Engl J Med. 2019;381(24):2327–2337. doi: 10.1056/NEJMoa1906661.
    1. Jou C, Shah R, Figueroa A, Patel JK. The role of inflammatory cytokines in cardiac arrest. J Intensive Care Med. 2020;35(3):219–224. doi: 10.1177/0885066618817518.
    1. Witten L, Gardner R, Holmberg MJ, Wiberg S, Moskowitz A, Mehta S, Grossestreuer AV, Yankama T, Donnino MW, Berg KM. Reasons for death in patients successfully resuscitated from out-of-hospital and in-hospital cardiac arrest. Resuscitation. 2019;136:93–99. doi: 10.1016/j.resuscitation.2019.01.031.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera